We are analyzing https://link.springer.com/chapter/10.1007/978-3-642-72153-3_3.

Title:
Clinical Trials with Blocked Ricin Immunotoxins | SpringerLink
Description:
The use of combination chemotherapy and the introduction of new cytotoxic agents has resulted in therapeutic advances for patients with cancer. Unfortunately, even with the development of innovative multi-drug treatment regimens and the increasing availability of...
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don't see any clear sign of profit-making.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Link.springer.com might have a hidden revenue stream, but it's not something we can detect.

Keywords {🔍}

google, scholar, pubmed, cas, ricin, cancer, lymphoma, lambert, article, cell, immunotoxin, nadler, grossbard, patients, blood, blattler, chapter, esseltine, marrow, antibblocked, therapy, phase, bone, res, clin, nonhodgkins, goldmacher, clinical, immunotoxins, blocked, transplantation, frankel, oncol, epstein, trial, research, autologous, human, med, ritz, leukemia, proc, privacy, cookies, content, information, publish, chemotherapy, download, anderson,

Topics {✒️}

anti-b4-br immunotoxin purging anti-b4-blocked ricin synergizes anti-my9-blocked ricin compared anti-pan t-cell immunotoxin immunotoxin anti-b4-blocked ricin anti-b4-blocked ricin therapy month download article/chapter long-term marrow cultures anti-my9-blocked ricin triantennary n-linked oligosaccharides create anti-tumor reagents hematopoietic stem-cell transplantation anti-cd6-blocked ricin anti-b4-blocked ricin anti-tumor agents ideally anti-b4blocked ricin immunotoxin monoclonal antibody-based therapies anti-breast cancer immunotoxin a-chain translocation activities anti-b4-br bone marrow treated privacy choices/manage cookies anti-b4blocked ricin bone marrow grafts b4-blocked ricin stem cell research b-lineage leukemia acute myeloid leukemia device instant download chapter clinical applications plant protein ricin n901-blocked ricin blocked ricin immunotoxins devita vt jr roy dc ricin a-chain drug-sensitive tumors tumor cell resistance leukemic progenitor cells malignant b-lymphocytes chronic lymphocytic leukemia download preview pdf european economic area aggressive treatment programs 4th international symposium elevated interstitial pressure standard dose mbacod reduced dose mbacod h65-rta immunoconjugate massachusetts general hospital

Questions {❓}

Freedman AS, Nadler LM (1993) Which patients with relapsed non-Hodgkin’s lymphoma benefit from high-dose therapy and hematopoietic stem-cell transplantation?

Schema {🗺️}

ScholarlyArticle:
      headline:Clinical Trials with Blocked Ricin Immunotoxins
      pageEnd:56
      pageStart:35
      image:https://media.springernature.com/w153/springer-static/cover/book/978-3-642-72153-3.jpg
      genre:
         Biomedical and Life Sciences
         Biomedical and Life Sciences (R0)
      isPartOf:
         name:Clinical Applications of Immunotoxins
         isbn:
            978-3-642-72153-3
            978-3-642-72155-7
         type:Book
      publisher:
         name:Springer Berlin Heidelberg
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:J. E. O’Toolei
            affiliation:
                  name:Massachusetts General Hospital
                  address:
                     name:Hematology-Oncology Unit, Massachusetts General Hospital, Boston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:D. Esseltine
            affiliation:
                  name:ImmunoGen, Inc.
                  address:
                     name:ImmunoGen, Inc., Cambridge, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:T. J. Lynch
            affiliation:
                  name:Massachusetts General Hospital
                  address:
                     name:Hematology-Oncology Unit, Massachusetts General Hospital, Boston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:J. M. Lambert
            affiliation:
                  name:ImmunoGen, Inc.
                  address:
                     name:ImmunoGen, Inc., Cambridge, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:M. L. Grossbard
            affiliation:
                  name:Massachusetts General Hospital
                  address:
                     name:Hematology-Oncology Unit, Massachusetts General Hospital, Boston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      keywords:Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Small Cell Lung Cancer, Maximum Tolerate Dose, Acute Myelogenous Leukemia
      description:The use of combination chemotherapy and the introduction of new cytotoxic agents has resulted in therapeutic advances for patients with cancer. Unfortunately, even with the development of innovative multi-drug treatment regimens and the increasing availability of both autologous bone marrow transplantation (ABMT) and peripheral blood stem cell transplantation (PBSCT), the clinician lacks the necessary tools to successfully combat the progression of malignancy in the majority of patients. Furthermore, substantial morbidity and potential mortality is associated with the use of these aggressive treatment programs. New anti-tumor agents ideally should circumvent the two major limitations of current therapy: devastating nonspecific side effects and tumor cell resistance.
      datePublished:1998
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
      context:https://schema.org
Book:
      name:Clinical Applications of Immunotoxins
      isbn:
         978-3-642-72153-3
         978-3-642-72155-7
Organization:
      name:Springer Berlin Heidelberg
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Massachusetts General Hospital
      address:
         name:Hematology-Oncology Unit, Massachusetts General Hospital, Boston, USA
         type:PostalAddress
      name:ImmunoGen, Inc.
      address:
         name:ImmunoGen, Inc., Cambridge, USA
         type:PostalAddress
      name:Massachusetts General Hospital
      address:
         name:Hematology-Oncology Unit, Massachusetts General Hospital, Boston, USA
         type:PostalAddress
      name:ImmunoGen, Inc.
      address:
         name:ImmunoGen, Inc., Cambridge, USA
         type:PostalAddress
      name:Massachusetts General Hospital
      address:
         name:Hematology-Oncology Unit, Massachusetts General Hospital, Boston, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:J. E. O’Toolei
      affiliation:
            name:Massachusetts General Hospital
            address:
               name:Hematology-Oncology Unit, Massachusetts General Hospital, Boston, USA
               type:PostalAddress
            type:Organization
      name:D. Esseltine
      affiliation:
            name:ImmunoGen, Inc.
            address:
               name:ImmunoGen, Inc., Cambridge, USA
               type:PostalAddress
            type:Organization
      name:T. J. Lynch
      affiliation:
            name:Massachusetts General Hospital
            address:
               name:Hematology-Oncology Unit, Massachusetts General Hospital, Boston, USA
               type:PostalAddress
            type:Organization
      name:J. M. Lambert
      affiliation:
            name:ImmunoGen, Inc.
            address:
               name:ImmunoGen, Inc., Cambridge, USA
               type:PostalAddress
            type:Organization
      name:M. L. Grossbard
      affiliation:
            name:Massachusetts General Hospital
            address:
               name:Hematology-Oncology Unit, Massachusetts General Hospital, Boston, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Hematology-Oncology Unit, Massachusetts General Hospital, Boston, USA
      name:ImmunoGen, Inc., Cambridge, USA
      name:Hematology-Oncology Unit, Massachusetts General Hospital, Boston, USA
      name:ImmunoGen, Inc., Cambridge, USA
      name:Hematology-Oncology Unit, Massachusetts General Hospital, Boston, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(138)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js

4.7s.

LINK . SPRINGER . COM {}